Gevo Corporate Update: Strengthened Balance Sheet

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
33
Gevo Corporate Update: Strengthened Balance Sheet

ENGLEWOOD, Colo., July 03, 2018 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO ) – As previously disclosed, Gevo entered into an At-the-Market Offering Agreement, dated February 13, 2018, as amended on June 20, 2018, June 25, 2018, and as further amended on June 28, 2018, with H.C. Wainwright & Co., LLC relating to shares of Gevo’s common stock, par value $0.01 per share (the “ATM Program”). During the month of June, Gevo sold 6,126,534 shares of common stock (after giving effect to the one-for-twenty reverse stock split effected on June 1, 2018) under the ATM Program for gross proceeds of approximately $36.3 million .

As of July 3, 2018, Gevo had cash and cash equivalents of approximately $41 million 1 and approximately 7,990,240 shares of common stock issued and outstanding, including the shares issued as part of the note conversions and warrant exercises described below.

2020 Notes Conversions

In June 2018, Gevo received conversion notices from the holders of its 12.0% convertible senior secured notes due 2020 (the “2020 Notes”) and converted an aggregate of approximately $3.2 million in aggregate principal amount of 2020 Notes for an aggregate of 260,793 shares of common stock.  These conversions reduced the outstanding principal amount of the 2020 Notes to approximately $13.55 million, a reduction of approximately 18.5% in the outstanding principal amount of the 2020 Notes since March 31, 2018. 

Warrant Exercises

Also during June 2018, Gevo received notices of exercise from holders of its Series A and K Warrants to purchase common stock to issue an aggregate of 300,510 shares of common stock for total gross proceeds of approximately $1.26 million.

Following these exercises, Series A Warrants to purchase 320 shares of common stock and Series K Warrants to purchase 3,990 shares of common stock remain outstanding at an exercise price of $3.80 per share.  During June, the total of all outstanding warrants for Gevo were reduced by approximately 84%. 

Path to Profitability and Use of Proceeds

Gevo intends to use a portion of its current cash and cash equivalents to pursue its previously disclosed strategy.  First, Gevo intends to deploy capital at its specialty production facility in Luverne, Minnesota (the “Luverne Facility”) to make certain changes and improvements to produce low-carbon ethanol side-by-side with low-carbon isobutanol.  By focusing on low-carbon ethanol in the near term, debottlenecking production, while adapting and optimizing the Luverne Facility’s energy and equipment infrastructure to use lower amounts of lower fossil-based energy sources, Gevo believes that it can increase revenues to make the Luverne Facility profitable on a non-GAAP Cash EBITDA basis. 2

Second, Gevo plans to deploy capital to continue to strategically develop its isobutanol and related hydrocarbon businesses.  In addition to low-carbon ethanol production, Gevo also believes that it could become profitable on a non-GAAP Cash EBITDA basis 2 if it is able to obtain binding offtake agreements for its isobutanol and related hydrocarbon products that justify an expansion of the Luverne Facility whereby, upon obtaining adequate additional funding, Gevo would convert the Luverne Facility primarily to the production of isobutanol at scale, with some percentage of such isobutanol volumes to be further processed into hydrocarbons such as its alcohol-to-jet fuel and isooctane products.

About Gevo

Gevo is a leading renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo’s strategy is to commercialize bio-based alternatives to petroleum-based products to allow for the optimization of fermentation facilities’ assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, MN. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, TX, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo is committed to a sustainable bio-based economy that meets society’s needs for plentiful food and clean air and water. Learn more at our website:  www.gevo.com .

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, statements related to Gevo’s path to profitability, Gevo’s ability to become profitable, Gevo’s strategies to become profitable, Gevo’s intended uses of its cash and cash equivalents, Gevo’s ability to obtain adequate funding for an expansion of the Luverne Facility the markets for Gevo’s products, Gevo’s ability to sell its products, and other statements that are not purely statements of historical fact.  These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2017, as amended, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

1 This amount is unaudited and preliminary, and does not present all information necessary for an understanding of Gevo’s financial condition as of July 3, 2018. Gevo’s estimate is based solely on information available to it as of July 3, 2018. Actual results for the quarter ending June 30, 2018 remain subject to the completion of management’s and Gevo’s audit committee’s final reviews and Gevo’s other financial closing procedures and the completion of the preparation of Gevo’s unaudited consolidated financial statements.

2 Cash EBITDA is a non-GAAP financial measure and is calculated by adding depreciation and non-cash stock compensation to GAAP (loss)/income from operations.

  Investor and Media Contact Shawn M. Severson Integra Investor Relations +1 415-226-7747 gevo@integra-ir.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 425

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 86

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 268

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 323

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 15

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 340

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading

Top 5 Most Recently Viewed Articles

Laugh Factory's Annual Free Thanksgiving Feast Returns to Hollywood

Updated Category News Views 239

Laugh Factory's Holiday Tradition: A Thanksgiving Feast The world-renowned Laugh Factory in Hollywood proudly continues its cherished tradition by hosting the 45th consecutive annual free Thanksgiving feast. This Thanksgiving, the club opens its doors for four seatings at 1 p.m., 3 p.m., 5 p.m., and 7 p.m., offering an incredible opportunity for community members to come...

Continue Reading
Recognizing Thomas Edwards Jr.: A Champion of Justice

Updated Category News Views 275

Celebrating Excellence in Legal Advocacy Attorney Thomas S. Edwards, Jr., a Senior Partner at Edwards & Ragatz, P.A., has been honored with the prestigious "Compassionate Gladiator Award" by the Florida Justice Association (FJA). This esteemed award is presented to legal professionals who exhibit exceptional dedication to their clients and the legal system, reflecting the...

Continue Reading
Growth Journey of Plant-Based Dairy: Trends and Insights

Updated Category News Views 283

Exploring the Plant-Based Dairy Products Market The plant-based dairy products market is witnessing remarkable growth, driven by evolving consumer preferences and increasing awareness regarding health benefits and sustainability practices. Initially valued at USD 20 billion, market experts project it to reach USD 34 billion by 2030, fueled by a promising CAGR of 9%...

Continue Reading
Catch the Excitement of Monster Jam at Northern Tool + Equipment

Updated Category News Views 138

Monster Jam Hits Northern Tool + Equipment in Oklahoma City Northern Tool + Equipment is thrilled to announce an upcoming event that promises to be packed with excitement and entertainment for the community. This special day will spotlight a legendary Monster Jam truck, bringing the high-octane thrill of motorsports to local fans. Exclusive Offers for Customers As part of...

Continue Reading
Analyzing NVIDIA’s Competitive Edge in Semiconductor Sector

Updated Category News Views 214

Understanding NVIDIA's Role in the Semiconductor Industry In the fast-paced world of technology, evaluation of companies within specific sectors is vital for investors and enthusiasts. This article focuses on NVIDIA (NASDAQ: NVDA), a leader in the Semiconductors & Semiconductor Equipment industry, and compares its performance with key competitors. By analyzing crucial...

Continue Reading